Geoffrey Parker
Director of Finance/CFO presso ALLOGENE THERAPEUTICS, INC.
Patrimonio netto: 5 M $ in data 31/03/2024
Profilo
Geoffrey M.
Parker is currently serving as an Independent Director at Perrigo Co. Plc since 2016, as a Director at Better Therapeutics LLC since 2021, and as an Executive VP, Chief Financial & Accounting Officer at Allogene Therapeutics, Inc. since 2023.
Previously, he held positions as an Independent Director at ChemoCentryx, Inc. from 2009 to 2022, as an Independent Director at Sunesis Pharmaceuticals, Inc. in 2016-2017, as a Director at Genoptix, Inc., and as an Independent Director at Genomic Health, Inc. from 2016 to 2019.
He also worked as an MD & Partner-Investment Banking Division at The Goldman Sachs Group, Inc. from 1997 to 2009, as the Chief Business Officer at InteKrin Therapeutics, Inc. from 2009 to 2010, as the Chief Financial Officer & Executive Vice President at Tricida, Inc. from 2020 to 2021, as a Vice President at Feibusch & Co., Inc. from 1995 to 1997, as the Chief Financial Officer & Executive Vice President at Anacor Pharmaceuticals LLC from 2009 to 2015, and as the Chief Financial Officer & Senior Vice President at Anacor, Inc. from 2012 to 2015.
Mr. Parker obtained his undergraduate degree from Dartmouth College and his MBA from Stanford Graduate School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 30/01/2024 | 819 590 ( 0.48% ) | 4 M $ | 31/03/2024 | |
PERRIGO CO. PLC
0.03% | 04/03/2024 | 47 084 ( 0.03% ) | 2 M $ | 31/03/2024 |
| 18/12/2023 | 1 085 138 ( 2.00% ) | 15 192 $ | 31/03/2024 |
Posizioni attive di Geoffrey Parker
| Società | Posizione | Inizio |
|---|---|---|
| PERRIGO COMPANY PLC | Director/Board Member | 07/11/2016 |
| ALLOGENE THERAPEUTICS, INC. | Director of Finance/CFO | 16/10/2023 |
Better Therapeutics LLC
 Better Therapeutics LLC Medical SpecialtiesHealth Technology Part of Better Therapeutics, Inc., Better Therapeutics LLC is a private company that focuses on clinical development and creating habits that heal to reduce the need for other treatments. The company is based in San Francisco, CA. The company is pioneers in the field of prescription digital therapeutics for treating a range of cardiometabolic diseases. The company was founded by David P. Perry and Kevin J. Appelbaum. Kevin J. Appelbaum has been the CEO of the company since 2015. Better Therapeutics was acquired by Mountain Crest Acquisition Corp. II on October 28, 2021 for $164.55 million. | Director/Board Member | 30/03/2021 |
Precedenti posizioni note di Geoffrey Parker
| Società | Posizione | Fine |
|---|---|---|
| BETTER THERAPEUTICS, INC. | Director/Board Member | 14/03/2024 |
| CHEMOCENTRYX, INC. | Director/Board Member | 20/10/2022 |
| GENOMIC HEALTH, INC. | Director/Board Member | 08/11/2019 |
| VIRACTA THERAPEUTICS, INC. | Director/Board Member | 31/12/2017 |
| ANACOR PHARMACEUTICALS INC | Director of Finance/CFO | 31/05/2015 |
Formazione di Geoffrey Parker
| Dartmouth College | Undergraduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| THE GOLDMAN SACHS GROUP, INC. | Finance |
| TRICIDA, INC. | Health Technology |
| PERRIGO COMPANY PLC | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| BETTER THERAPEUTICS, INC. | Health Technology |
| Aziende private | 9 |
|---|---|
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Genoptix, Inc.
 Genoptix, Inc. Medical SpecialtiesHealth Technology Genoptix, Inc. provides specialized oncology diagnostics services. It offers a range of customizable clinical trial, custom assay development and companion diagnostics development services. The company was founded in 1999 by Tina S. Nova and is headquartered in Carlsbad, CA. | Health Technology |
Genomic Health, Inc.
 Genomic Health, Inc. Medical SpecialtiesHealth Technology Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA. | Health Technology |
InteKrin Therapeutics, Inc.
 InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology InteKrin Therapeutics, Inc. develops and commercializes therapeutics for metabolic and immune disorders. It develops therapeutics for diabetes, insulin resistance and multiple sclerosis. The company was founded by Dennis M. Lanfear and Christos S. Mantzoros in 2005 and is headquartered in Palo Alto, CA. | Health Technology |
Feibusch & Co., Inc.
 Feibusch & Co., Inc. Investment ManagersFinance Feibusch & Co., Inc. operates as a venture capital firm. The company is headquartered in Larkspur, CA. | Finance |
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Anacor, Inc.
 Anacor, Inc. Pharmaceuticals: MajorHealth Technology Anacor, Inc. manufactures pharmaceutical products. The American company was founded by Tat C. Choi. | Health Technology |
Better Therapeutics LLC
Better Therapeutics LLC Medical SpecialtiesHealth Technology Part of Better Therapeutics, Inc., Better Therapeutics LLC is a private company that focuses on clinical development and creating habits that heal to reduce the need for other treatments. The company is based in San Francisco, CA. The company is pioneers in the field of prescription digital therapeutics for treating a range of cardiometabolic diseases. The company was founded by David P. Perry and Kevin J. Appelbaum. Kevin J. Appelbaum has been the CEO of the company since 2015. Better Therapeutics was acquired by Mountain Crest Acquisition Corp. II on October 28, 2021 for $164.55 million. | Health Technology |
- Borsa valori
- Insiders
- Geoffrey Parker
